Though none of these ABCG2-specific efforts have yet resulted in improvements in patient care, the broader concept of circumventing drug efflux pump-mediated resistance has led to the development and approval of cabazitaxel for prostate cancer. The gene discussed is ABCG2; the disease is Familial prostate cancer.